Q-omics provides the consensus-scored MMADHCP1 profile across patient tissues and cancer cell-line models. MMADHCP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MMADHCP1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, MMADHCP1 RNA expression shows 6,171 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, HNSC, and STAD as cancer lineages where MMADHCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMADHCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMADHCP1 survival associations across molecular data types. MMADHCP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMADHCP1 RNA expression–survival associations across cancer types. High MMADHCP1 expression shows unfavorable associations in MESO, UVM, KIRP, KIRC, THYM and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for MMADHCP1 RNA expression.
This table summarizes MMADHCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MMADHCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMADHCP1 shows higher tumor expression in HNSC, BRCA, LUAD and LIHC. The HNSC box plot shows higher MMADHCP1 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .004).
This table shows molecular features associated with MMADHCP1 in patient tissues and cancer cell lines. In patient samples, MMADHCP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
